5 Segment reporting

The Group’s activities are in one segment, Biopharmaceuticals.

There are no other significant classes of business, either singularly or in aggregate. The Chief Operating Decision Makers, that being the Executive Committee, review the operating results and operating plans, and make resource allocation decisions on a company-wide basis, therefore UCB operates as one segment.

Enterprise-wide disclosures about product sales, geographic areas and revenues from major customers are presented below.

5.1 Product sales information

Net Sales consist of the following:

 

 

 

€ million

2018

2017

Cimzia®

1 446

1 424

Vimpat®

1 099

976

Keppra® (including Keppra® XR)

790

778

Neupro®

321

314

Briviact®

142

87

Zyrtec® (including Zyrtec-D®/Cirrus®)

101

103

Xyzal®

90

104

Other products

323

368

Designated hedges reclassified to net sales

100

28

Total net sales

4 412

4 182

 

 

 

5.2 Geographic information

The table below shows net sales in each geographic market in which customers are located:

 

 

 

€ million

2018

2017

U.S.

2 158

2 069

Germany

334

319

Europe – other (excluding Belgium)

331

322

Japan

305

292

Spain

179

175

France (including French territories)

163

161

China

151

134

Italy

149

141

U.K. and Ireland

131

133

Belgium

39

37

Other countries

372

371

Designated hedges reclassified to net sales

100

28

Total net sales

4 412

4 182

 

 

 

The table below illustrates the property, plant and equipment in each geographic market in which the assets are located:

 

 

 

€ million

2018

2017

Belgium

296

260

Switzerland

295

298

U.K. and Ireland

68

40

U.S.

54

32

Japan

30

23

China

24

12

Other countries

38

8

Total

805

673

 

 

 

5.3 Information about major customers

UCB has 1 customer which individually accounts for more than 15% of the total net sales at the end of 2018.

In the U.S., sales to 3 wholesalers accounted for approximately 75% of U.S. sales (2017: 74%).